Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2002
08/22/2002WO2002064575A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
08/22/2002WO2002064572A1 Quinazolines as mmp-13 inhibitors
08/22/2002WO2002064565A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
08/22/2002WO2002064564A1 Benzo'f!isoindole derivatives with affinity to the ep4 receptor
08/22/2002WO2002064557A2 New crystal forms of oxcarbazepine and processes for their preparation
08/22/2002WO2002064547A2 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
08/22/2002WO2002064546A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
08/22/2002WO2002064545A1 Acylated indanyl amines and their use as pharmaceuticals
08/22/2002WO2002064543A2 Novel succinate salt of o-desmethyl-venlafaxine
08/22/2002WO2002064213A1 Use of flumazenil to produce a medicament for the treatment of cocaine dependency
08/22/2002WO2002064169A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
08/22/2002WO2002064146A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
08/22/2002WO2002064141A1 New use of iloperidone
08/22/2002WO2002064139A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
08/22/2002WO2002064135A1 Heterocyclic inhibitors of glycine transporter 2
08/22/2002WO2002064134A2 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
08/22/2002WO2002064128A1 Treatment of diseases characterized by excessive or insufficient cell death
08/22/2002WO2002064126A2 Method of treating of demyelinating diseases or conditions
08/22/2002WO2002064124A2 Medicament formulation containing a muscarinic agonist
08/22/2002WO2002064109A2 Mucoadhesive pharmaceutical formulations
08/22/2002WO2002064094A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
08/22/2002WO2002064085A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
08/22/2002WO2002064083A2 Synthesis of 3-amino-thalidomide and its enantiomers
08/22/2002WO2002053139A3 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
08/22/2002WO2002045652A3 Tyrosine kinase inhibitors
08/22/2002WO2002042280A3 Pyrimidine derivatives
08/22/2002WO2002040471A3 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
08/22/2002WO2002036170A3 Vector system for transducing the positive neurons
08/22/2002WO2002032893A3 Piperidine compounds as anti-allergic
08/22/2002WO2002032377A3 Estrogen receptor modulators
08/22/2002WO2002022141A3 Xenon as medicament
08/22/2002WO2002018401A3 Novel synthetic gangliosides
08/22/2002WO2002002773A3 Dual specificity antibodies and methods of making and using
08/22/2002WO2002002755A3 Regulation of human thimet oligopeptidase-like enzyme
08/22/2002WO2002000872A3 Compositions and methods for treating or detecting degenerative diseases of the motor neurons
08/22/2002WO2001087328A3 Interleukin-1 inhibitors in the treatment of diseases
08/22/2002WO2001085204A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
08/22/2002WO2001085203A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
08/22/2002WO2001074903A3 Cd20/ige-receptor like molecules and uses thereof
08/22/2002WO2000059908A3 Pyrazolopyrimidines as crf antagonists
08/22/2002WO2000035423A9 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
08/22/2002WO2000032239A9 Hapten-carrier conjugates for treating and preventing nicotine addiction
08/22/2002WO2000023092A9 Contulakin-g, analogs thereof and uses therefor
08/22/2002US20020116724 Nucleotide sequences codingolypeptide for use in the diagnosis and prevention of psoriasis and venous ulcers
08/22/2002US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole
08/22/2002US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects
08/22/2002US20020115727 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
08/22/2002US20020115726 Methods and compositions for treating depression and other disorders using optically pure (-) -bupropion
08/22/2002US20020115725 Methods and compositions for regulating memory consolidation
08/22/2002US20020115721 Alkyl carboxy amino acid analogs of glutamic acid; treating neurological, neuropsychological, neuropsychiatric, neurodegenerative, neuropsychopharmacological and functional disorders; postsynaptic glutamate receptor
08/22/2002US20020115715 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
08/22/2002US20020115710 Composition and method
08/22/2002US20020115703 Administering an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable ester or salt thereof, such as atipamezole, analogs of idazoxan, and analogs of efaroxan.
08/22/2002US20020115701 Have antipyretic action, analgesic action, antiinflammatory action, and particularly, selective inhibitory action on cyclooxygenase-2; ketomethylene intermediates
08/22/2002US20020115697 Azabicyclic compounds used in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.
08/22/2002US20020115684 2, 7-naphthyridine derivatives
08/22/2002US20020115683 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
08/22/2002US20020115682 Especially Alzheimer's disease; using hydrogenated pyrido (4,3-b) indole derivatives
08/22/2002US20020115670 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
08/22/2002US20020115667 Treatment of disorders associated with glycolipid accumulation, such as Niemann-Pick Type C disease by administering an inhibitor of glucosylceramide synthesis, such as N-butyldeoxynojirimycin
08/22/2002US20020115665 Contacting the calpain with an effective amount of an HIV protease inhibitor,
08/22/2002US20020115662 Delta-opioid or mu-opioid receptor modulators; useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of respiratory diseases.
08/22/2002US20020115660 Labled isotopes of phenyl 4-(1,4-diazepin-1-yl)-2-amino phenyl sulfone derivatives used in nuclear magnetic resonance imaging and positron emission tomography
08/22/2002US20020115654 New compounds, their preparation and use
08/22/2002US20020115652 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
08/22/2002US20020115643 Such as enantiomorphs of 4-fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone; antiproliferative/anticancer agents
08/22/2002US20020115641 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
08/22/2002US20020115635 Modulation of GSK-3beta activity and its different uses
08/22/2002US20020115617 Methods for the prevention and / or the treatment of glutamate cytotoxicity
08/22/2002US20020115616 Inhibit beta-secretase to reduce beta amyloid peptide concentrations and reduce the amyloid plaques and neuro-fibrillary tangles; Alzheimer's disease; stroke; Down' syndrome; amyotrophic lateral sclerosis; brain disorders
08/22/2002US20020115605 Novel peptide with effects on cerebral health
08/22/2002US20020115603 Methods and compositions for the treatment of peripheral artery disease
08/22/2002US20020115600 Inhibitors of memapsin 2 and use thereof
08/22/2002US20020115594 Peptide antagonists at glutamate and NMDA receptors
08/22/2002US20020115223 In vitro system for determining formation of abeta amyloid
08/22/2002US20020115186 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects
08/22/2002US20020115183 Enzymatic protien for us ein prevention of tumor metastasis
08/22/2002US20020115135 Synapse related glycoproteins
08/22/2002US20020115102 Novel protein
08/22/2002US20020114848 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues
08/22/2002US20020114837 Galenic composition for low bioavailability medicaments
08/22/2002US20020114836 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
08/22/2002US20020114792 Alpha-2-macroglobulin therapies and drug screening methods for Alzheimer's disease
08/22/2002US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases
08/22/2002US20020114780 Methods of increasing distribution of therapeutic agents
08/22/2002DE10108215A1 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym A pharmaceutical combination of antagonists of angiotensin II inhibitors and angiotensin II converting enzyme
08/22/2002DE10104584A1 Medane-Gene und- Proteine Medane genes and- proteins
08/22/2002DE10100053A1 Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen Use of enzyme inhibitors of the dipeptidyl peptidase IV as well as the aminopeptidase N and pharmaceutical preparations thereof for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative diseases and processes
08/22/2002DE10055857A1 Neue pharmazeutische Depotformulierung New pharmaceutical depot formulation
08/22/2002CA2856986A1 Post-partum mammalian placenta, its use and placental stem cells therefrom
08/22/2002CA2666611A1 Novel succinate salt of o-desmethyl-venlafaxine
08/22/2002CA2438712A1 Method of treating of demyelinating diseases or conditions
08/22/2002CA2438590A1 Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
08/22/2002CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/22/2002CA2438219A1 Sequences involved in phenomena of tumour suppression, tumour reversion apoptosis and/or virus resistance and their use as medicines
08/22/2002CA2438215A1 Putative human enzymes
08/22/2002CA2438153A1 Post-partum mammalian placenta, its use and placental stem cells therefrom
08/22/2002CA2437873A1 Neurotonin and use thereof
08/22/2002CA2437811A1 Human g-protein chemokine receptor (ccr5) hdgnr10
08/22/2002CA2437588A1 Triazolo compounds as mmp inhibitors